Seaport Global Securities restated their buy rating on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) in a research report report published on Tuesday morning. They currently have a $42.00 target price on the stock. Seaport Global Securities also issued estimates for Pacira Pharmaceuticals’ FY2018 earnings at ($0.52) EPS.
A number of other analysts have also recently weighed in on PCRX. Wedbush reaffirmed a buy rating and set a $80.00 target price on shares of Pacira Pharmaceuticals in a research note on Monday, November 20th. Mizuho cut shares of Pacira Pharmaceuticals from a buy rating to a neutral rating and reduced their price objective for the stock from $53.00 to $44.00 in a research note on Wednesday, November 29th. Canaccord Genuity set a $42.00 price objective on shares of Pacira Pharmaceuticals and gave the stock a hold rating in a research note on Wednesday, November 29th. JPMorgan Chase & Co. assumed coverage on shares of Pacira Pharmaceuticals in a research note on Monday, December 18th. They issued a neutral rating and a $47.00 price objective on the stock. Finally, BidaskClub cut shares of Pacira Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, December 20th. Three investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and eight have given a buy rating to the company’s stock. Pacira Pharmaceuticals currently has a consensus rating of Hold and an average price target of $44.06.
Shares of Pacira Pharmaceuticals (NASDAQ PCRX) opened at $32.30 on Tuesday. Pacira Pharmaceuticals has a one year low of $27.80 and a one year high of $52.47. The company has a debt-to-equity ratio of 0.99, a quick ratio of 6.22 and a current ratio of 6.96.
Pacira Pharmaceuticals (NASDAQ:PCRX) last posted its earnings results on Wednesday, February 28th. The company reported $0.38 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.46. The firm had revenue of $79.08 million for the quarter, compared to analysts’ expectations of $79.06 million. Pacira Pharmaceuticals had a negative net margin of 14.87% and a negative return on equity of 8.55%. The company’s revenue was up 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.09 earnings per share. equities analysts forecast that Pacira Pharmaceuticals will post -0.59 earnings per share for the current year.
In related news, CEO David M. Stack sold 28,885 shares of the business’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $40.19, for a total value of $1,160,888.15. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 6.60% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Rice Hall James & Associates LLC lifted its holdings in Pacira Pharmaceuticals by 18.4% in the fourth quarter. Rice Hall James & Associates LLC now owns 323,769 shares of the company’s stock valued at $14,780,000 after buying an additional 50,335 shares during the period. Mesirow Financial Investment Management Equity Management lifted its holdings in Pacira Pharmaceuticals by 5.1% in the fourth quarter. Mesirow Financial Investment Management Equity Management now owns 410,561 shares of the company’s stock valued at $18,742,000 after buying an additional 19,876 shares during the period. Legacy Capital Partners Inc. lifted its holdings in Pacira Pharmaceuticals by 6.5% in the fourth quarter. Legacy Capital Partners Inc. now owns 50,493 shares of the company’s stock valued at $2,305,000 after buying an additional 3,100 shares during the period. Epoch Investment Partners Inc. lifted its holdings in Pacira Pharmaceuticals by 195.7% in the third quarter. Epoch Investment Partners Inc. now owns 535,999 shares of the company’s stock valued at $20,127,000 after buying an additional 354,728 shares during the period. Finally, State of Wisconsin Investment Board lifted its holdings in Pacira Pharmaceuticals by 35.9% in the fourth quarter. State of Wisconsin Investment Board now owns 39,400 shares of the company’s stock valued at $1,799,000 after buying an additional 10,400 shares during the period.
ILLEGAL ACTIVITY NOTICE: This story was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this story on another domain, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The correct version of this story can be accessed at https://www.dispatchtribunal.com/2018/03/24/seaport-global-securities-reiterates-buy-rating-for-pacira-pharmaceuticals-pcrx.html.
About Pacira Pharmaceuticals
Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.
Receive News & Ratings for Pacira Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.